Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months. Cathie Wood's ARK increased its stake in the company by 8% in the fourth quarter, entering 2026 with a $10.5 million position. Crispr Therapeutics Ag (NASDAQ:CRSP) has the first-mover advantage in the gene editing and gene therapy industries with its CRISPR-based treatment approved by the FDA. Its CASGEVY therapy for severe sickle cell disease and beta-thalassemia is already generating revenue through its partnership with Vertex. Crispr Therapeutics Ag (NASDAQ:CRSP) has a strong pipeline and an advanced technology to edit cells both outside the body. Crispr Therapeutics Ag (NASDAQ:CRSP) saw an increase in hedge fund sentiment in the fourth quarter, as 32 funds ended the quarter with the stock in their portfolios, up from 31 funds in the prior quarter. Contrarius Global Equity Fund s
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics (CRSP) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $110.00 price target on the stock, up from $105.00.MarketBeat
- A Look At CRISPR Therapeutics (CRSP) Valuation After Upsized US$550 Million Convertible Note Offering [Yahoo! Finance]Yahoo! Finance
- Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- CRSP's page on the SEC website